| Target: | SMITHKLINE BEECHAM PLC | SIC Codes: | 2833 2834 0 0 0 |
| Country: | United Kingdom | Industrial Sectors: | Pharmaceuticals |
| Activities: | PHARMACEUTICALS/HEALTHCARE PRODUCTS/RESEARCH & MANUFACTURE | ||
| Bidder: | GLAXO WELLCOME PLC | ||
| Country: | United Kingdom | SIC Codes: | 2833 2834 0 0 0 |
| Activities: | PHARMACEUTICALS RESEARCH & DEVELOPMENT & MANUFACTURE | ||
| Date Announced: | 2000/01/17 | Date Completed: | 2000/12/27 |
| Deal Status: | Completed | Deal Type: | Pub. scheme |
| Deal Attitude: | Friendly | Cross Border: | No |
| % Capital Owned: | 0 | % Capital Bid For: | 100 |
| Competitive Status: | Single bidder | ||
| Regulatory Referral: | Conditions Imposed by Industry/Competition Authorities | ||
| Consideration Type: | Ordinary Shares | ||
| Deal Value (m) | Rate to STG 1.000 | Target Financials (m) | Rate to STG 1.000 | ||
| UK Sterling | UK Sterling | ||||
| Ordinary Offer Value | 46477.05 | Sales | 8445 | ||
| Other Equity Value | 0.000 | Depreciation/Amortisation | 0 | ||
| Total Equity Value | 46477.05 | Operating Profit | 1968 | ||
| Net Debt | 777 | NPBT | 1903 | ||
| Minorities | 111 | NPAT | 1384 | ||
| Firm Value | 47365.05 | Net Income | 1384 | ||
| Shareholders Funds | 3180 | ||||
| Price Ratios | Firm Value Ratios | ||||
| Price/Sales | 5.5 | Firm Value/Sales | 5.61 | ||
| Price/NPAT | 33.58 | Firm Value/EBITDA | 0 | ||
| Price/Book | 14.62 | Firm Value/EBIT | 24.07 | ||
| Accounts Source: | 12 MONTHS TO 30/09/1999 (PRE-EXCEPTIONALS) | Reliability: | Unaudited |
| Deal Value Source: | PRESS RELEASE (17/01/2000) | Reliability: | Accurate |